Drug Profile
PKI 402
Alternative Names: PF-04979064; PI3K inhibitors - Wyeth; PKI-402; TGX 221; TMZ-221Latest Information Update: 21 May 2022
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer; Wyeth
- Class 3-ring heterocyclic compounds; Naphthyridines; Pyrimidines; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arterial thrombosis; Cancer
Most Recent Events
- 08 Apr 2022 Pharmacodynamics data from a preclinical trial in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research - II(AACR-2022)
- 22 Jun 2020 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 111th Annual Meeting of the American Association for Cancer Research - II(AACR-2020)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA